Accelerate Diagnostics (NASDAQ:AXDX) Now Covered by StockNews.com

StockNews.com assumed coverage on shares of Accelerate Diagnostics (NASDAQ:AXDX) in a research note released on Tuesday. The firm issued a hold rating on the medical research company’s stock.

Separately, BTIG Research raised shares of Accelerate Diagnostics to a “strong-buy” rating in a report on Wednesday, December 11th.

Accelerate Diagnostics Stock Performance

NASDAQ:AXDX opened at $1.24 on Tuesday. Accelerate Diagnostics has a fifty-two week low of $0.73 and a fifty-two week high of $2.09. The firm has a market cap of $31.05 million, a PE ratio of -0.43 and a beta of 0.59. The business has a 50 day moving average price of $1.31 and a 200-day moving average price of $1.54.

Insider Transactions at Accelerate Diagnostics

In other Accelerate Diagnostics news, Director John Patience purchased 200,000 shares of the company’s stock in a transaction that occurred on Tuesday, December 3rd. The stock was bought at an average price of $1.57 per share, with a total value of $314,000.00. Following the completion of the purchase, the director now directly owns 653,224 shares of the company’s stock, valued at $1,025,561.68. The trade was a 44.13 % increase in their position. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Corporate insiders own 43.60% of the company’s stock.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Accelerate Diagnostics stock. Y Intercept Hong Kong Ltd purchased a new stake in shares of Accelerate Diagnostics, Inc. (NASDAQ:AXDX) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 19,866 shares of the medical research company’s stock, valued at approximately $34,000. Y Intercept Hong Kong Ltd owned 0.08% of Accelerate Diagnostics at the end of the most recent reporting period. Institutional investors and hedge funds own 17.14% of the company’s stock.

Accelerate Diagnostics Company Profile

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.